David Silverman / Getty Amgen will buy Otezla, Celgene‘s flagship psoriasis drug, for $13.4 billion — or about $11.2 billion after future cash tax benefits. The deal sweetens Celgene’s case to antitrust officials as it seeks approval for a $74 billion merger with Bristol-Myers Squibb, which was first announced in January 2019. Shares of Celgene […]